18 results on '"Herrera, Bobby Brooke"'
Search Results
2. High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses
- Author
-
Akanmu, Sulaimon, Herrera, Bobby Brooke, Chaplin, Beth, Ogunsola, Sade, Osibogun, Akin, Onawoga, Fatima, John-Olabode, Sarah, Akase, Iorhen E., Nwosu, Augustina, Hamel, Donald J., Chang, Charlotte A., and Kanki, Phyllis J.
- Published
- 2023
- Full Text
- View/download PDF
3. Dendritic Cells Pulsed with HAM/TSP Exosomes Sensitize CD4 T Cells to Enhance HTLV-1 Infection, Induce Helper T-Cell Polarization, and Decrease Cytotoxic T-Cell Response.
- Author
-
Joseph, Julie, Premeaux, Thomas A., Tandon, Ritesh, Murphy, Edward L., Bruhn, Roberta, Nicot, Christophe, Herrera, Bobby Brooke, Lemenze, Alexander, Alatrash, Reem, Baffour Tonto, Prince, Ndhlovu, Lishomwa C., and Jain, Pooja
- Subjects
IMMUNE checkpoint proteins ,SPINAL cord diseases ,EXTRACELLULAR vesicles ,PATHOLOGY ,T cells ,T helper cells - Abstract
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive demyelinating disease of the spinal cord due to chronic inflammation. Hallmarks of disease pathology include dysfunctional anti-viral responses and the infiltration of HTLV-1-infected CD4+ T cells and HTLV-1-specific CD8+ T cells in the central nervous system. HAM/TSP individuals exhibit CD4+ and CD8+ T cells with elevated co-expression of multiple inhibitory immune checkpoint proteins (ICPs), but ICP blockade strategies can only partially restore CD8+ T-cell effector function. Exosomes, small extracellular vesicles, can enhance the spread of viral infections and blunt anti-viral responses. Here, we evaluated the impact of exosomes isolated from HTLV-1-infected cells and HAM/TSP patient sera on dendritic cell (DC) and T-cell phenotypes and function. We observed that exosomes derived from HTLV-infected cell lines (OSP2) elicit proinflammatory cytokine responses in DCs, promote helper CD4+ T-cell polarization, and suppress CD8+ T-cell effector function. Furthermore, exosomes from individuals with HAM/TSP stimulate CD4+ T-cell polarization, marked by increased Th1 and regulatory T-cell differentiation. We conclude that exosomes in the setting of HAM/TSP are detrimental to DC and T-cell function and may contribute to the progression of pathology with HTLV-1 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The Adaptive Immune Response against Bunyavirales.
- Author
-
Alatrash, Reem and Herrera, Bobby Brooke
- Subjects
- *
IMMUNE response , *T cells , *VACCINE effectiveness , *ARTHROPOD vectors , *VACCINE development , *ANTIBODY formation , *AVIAN influenza - Abstract
The Bunyavirales order includes at least fourteen families with diverse but related viruses, which are transmitted to vertebrate hosts by arthropod or rodent vectors. These viruses are responsible for an increasing number of outbreaks worldwide and represent a threat to public health. Infection in humans can be asymptomatic, or it may present with a range of conditions from a mild, febrile illness to severe hemorrhagic syndromes and/or neurological complications. There is a need to develop safe and effective vaccines, a process requiring better understanding of the adaptive immune responses involved during infection. This review highlights the most recent findings regarding T cell and antibody responses to the five Bunyavirales families with known human pathogens (Peribunyaviridae, Phenuiviridae, Hantaviridae, Nairoviridae, and Arenaviridae). Future studies that define and characterize mechanistic correlates of protection against Bunyavirales infections or disease will help inform the development of effective vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Continued Transmission of Zika Virus in Humans in West Africa, 1992-2016
- Author
-
Herrera, Bobby Brooke, Chang, Charlotte A., Hamel, Donald J., Mboup, Souleymane, Ndiaye, Daouda, Imade, Godwin, Okpokwu, Jonathan, Agbaji, Oche, Bei, Amy K., and Kanki, Phyllis J.
- Published
- 2017
6. Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.
- Author
-
Joseph, Julie, Sandel, Grace, Kulkarni, Ratuja, Alatrash, Reem, Herrera, Bobby Brooke, and Jain, Pooja
- Subjects
HEPATITIS C virus ,KAPOSI'S sarcoma-associated herpesvirus ,HTLV ,EPSTEIN-Barr virus ,VIRUS diseases ,HUMAN papillomavirus ,AIDS - Abstract
Infectious agents, notably viruses, can cause or increase the risk of cancer occurrences. These agents often disrupt normal cellular functions, promote uncontrolled proliferation and growth, and trigger chronic inflammation, leading to cancer. Approximately 20% of all cancer cases in humans are associated with an infectious pathogen. The International Agency for Research on Cancer (IARC) recognizes seven viruses as direct oncogenic agents, including Epstein–Barr Virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human T-cell leukemia virus type-1 (HTLV-1), human papilloma virus (HPV), hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus type 1 (HIV-1). Most viruses linked to increased cancer risk are typically transmitted through contact with contaminated body fluids and high-risk behaviors. The risk of infection can be reduced through vaccinations and routine testing, as well as recognizing and addressing risky behaviors and staying informed about public health concerns. Numerous strategies are currently in pre-clinical phases or undergoing clinical trials for targeting cancers driven by viral infections. Herein, we provide an overview of risk factors associated with increased cancer incidence in people living with HIV (PLWH) as well as other chronic viral infections, and contributing factors such as aging, toxicity from ART, coinfections, and comorbidities. Furthermore, we highlight both antibody- and cell-based strategies directed against virus-induced cancers while also emphasizing approaches aimed at discovering cures or achieving complete remission for affected individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Development and Validation of a Rapid Screening Test for HTLV-I IgG Antibodies.
- Author
-
Herrera, Bobby Brooke, Mayoral, Rafaela, and Brites, Carlos
- Subjects
- *
HTLV , *IMMUNOGLOBULINS , *HTLV-I , *HEPATITIS A virus , *IMMUNOGLOBULIN G , *HEPATITIS C virus , *HEPATITIS B virus - Abstract
Initial diagnosis of human T cell lymphotropic virus (HTLV) infections is mainly based by detecting antibodies in plasma or serum using laboratory-based methods. The aim of this study was to develop and evaluate a rapid screening test for HTLV-I antibodies. Our rapid screening test uses HTLV-I p24 antigen conjugated to gold nanoparticles and an anti-human IgG antibody immobilized to a nitrocellulose strip to detect human HTLV-I p24-specific IgG antibodies via immunochromatography. Performance of the rapid screening test for HTLV-I was conducted on a total of 118 serum specimens collected in Salvador, Bahia, the epicenter for HTLV-1 infection in Brazil. Using a Western blot test as the comparator, 55 serum specimens were HTLV-I positive, 5 were HTLV-I and HTLV-II positive, and 58 were negative. The sensitivity of the rapid screening test for HTLV-1 was 96.7% and the specificity was 100%. The rapid screening test did not show cross-reaction with serum specimens from individuals with potentially interfering infections including those caused by HTLV-II, HIV-I, HIV-II, hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, Epstein–Barr virus, SARS-CoV-2, Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Toxoplasma gondii, and Plasmodium falciparum. The rapid screening test also did not show cross-reaction with potentially interfering substances. Strategies for HTLV diagnosis in non- and high-endemic areas can be improved with low-cost, rapid screening tests. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Monoclonal antibody pairs against SARS-CoV-2 for rapid antigen test development.
- Author
-
Salcedo, Nol, Reddy, Ankita, Gomez, Adam R., Bosch, Irene, and Herrera, Bobby Brooke
- Subjects
SARS-CoV-2 ,COVID-19 testing ,MONOCLONAL antibodies ,COVID-19 ,PUBLIC health surveillance - Abstract
Background: The focus on laboratory-based diagnosis of coronavirus disease 2019 (COVID-19) warrants alternative public health tools such as rapid antigen tests. While there are a number of commercially available antigen tests to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), all cross-react with the genetically similar SARS-CoV-1 or require an instrument for results interpretation. Methodology/Principal findings: We developed and validated rapid antigen tests that use pairs of murine-derived monoclonal antibodies (mAbs), along with gold nanoparticles, to detect SARS-CoV-2 with or without cross-reaction to SARS-CoV-1 and other coronaviruses. In this development, we demonstrate a robust antibody screening methodology for the selection of mAb pairs that can recognize SARS-CoV-2 spike (S) and nucleocapsid (N) proteins. Linear epitope mapping of the mAbs helped elucidate SARS-CoV-2 S and N interactions in lateral flow chromatography. A candidate rapid antigen test for SARS-CoV-2 N was validated using nasal swab specimens that were confirmed positive or negative by quantitative reverse-transcription polymerase chain reaction (RT-PCR). Test results were image-captured using a mobile phone and normalized signal pixel intensities were calculated; signal intensities were inversely correlated to RT-PCR cycle threshold (Ct) value. Conclusion/Significance: Overall, our results suggest that the rapid antigen test is optimized to detect SARS-CoV-2 N during the acute phase of COVID-19. The rapid antigen tests developed in this study are alternative tools for wide scale public health surveillance of COVID-19. Author summary: The delays in diagnostic testing and lack of proper surveillance during the COVID-19 pandemic have contributed, in part, to the unprecedented death toll and impediment to wellbeing. As asymptomatic individuals have contributed to a large portion of disease spread, improved public health tools for widespread screening are necessary to maintain low transmission levels. We developed new rapid antigen tests that can be administered in less than 15 minutes without instrumentation, offering potential for frequent asymptomatic screening at-home and for point-of-care use in high-traffic areas such as schools, hospitals, and airports. The SARS-CoV-2 monoclonal antibody screening methodology resulted in pairs with or without cross-reaction to SARS-CoV-1, offering new opportunities for public health tools such as wide scale surveillance. This paper provides important insights for nanoparticle-based immunochromatographic assays. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Comparative Evaluation of Rapid Isothermal Amplification and Antigen Assays for Screening Testing of SARS-CoV-2.
- Author
-
Salcedo, Nol, Sena, Brena F., Qu, Xiying, and Herrera, Bobby Brooke
- Subjects
COVID-19 testing ,GENE amplification ,ANTIGENS ,HIGH throughput screening (Drug development) ,SARS-CoV-2 ,DETECTION limit - Abstract
Human transmission of SARS-CoV-2 and emergent variants of concern continue to occur globally, despite mass vaccination campaigns. Public health strategies to reduce virus spread should therefore rely, in part, on frequent screening with rapid, inexpensive, and sensitive tests. We evaluated two digitally integrated rapid tests and assessed their performance using stored nasal swab specimens collected from individuals with or without COVID-19. An isothermal amplification assay combined with a lateral flow test had a limit of detection of 10 RNA copies per reaction, and a positive percent agreement (PPA)/negative percent agreement (NPA) during the asymptomatic and symptomatic phases of 100%/100% and 95.83/100%, respectively. Comparatively, an antigen-based lateral flow test had a limit of detection of 30,000 copies and a PPA/NPA during the asymptomatic and symptomatic phases of 82.86%/98.68% and 91.67/100%, respectively. Both the isothermal amplification and antigen-based lateral flow tests had optimized detection of SARS-CoV-2 during the peak period of transmission; however, the antigen-based test had reduced sensitivity in clinical samples with qPCR Ct values greater than 29.8. Low-cost, high-throughput screening enabled by isothermal amplification or antigen-based techniques have value for outbreak control. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Serotype-specific detection of dengue viruses in a nonstructural protein 1-based enzyme-linked immunosorbent assay validated with a multi-national cohort.
- Author
-
Bosch, Irene, Reddy, Ankita, de Puig, Helena, Ludert, Juan E., Perdomo-Celis, Federico, Narváez, Carlos F., Versiani, Alice, Fandos, Diana, Nogueira, Mauricio L., Singla, Mohit, Lodha, Rakesh, Medigeshi, Guruprasad R., Lorenzana, Ivette, Ralde, Hugo Vicente, Gélvez-Ramírez, Margarita, Villar, Luis A., Hiley, Megan, Mendoza, Laura, Salcedo, Nol, and Herrera, Bobby Brooke
- Subjects
ENZYME-linked immunosorbent assay ,VIRAL proteins ,DENGUE viruses ,MONOCLONAL antibodies ,IMMUNE response ,PARACOCCIDIOIDOMYCOSIS ,DENGUE hemorrhagic fever - Abstract
Background: Dengue virus (DENV) infections pose one of the largest global barriers to human health. The four serotypes (DENV 1–4) present different symptoms and influence immune response to subsequent DENV infections, rendering surveillance, risk assessments, and disease control particularly challenging. Early diagnosis and appropriate clinical management is critical and can be achieved by detecting DENV nonstructural protein 1 (NS1) in serum during the acute phase. However, few NS1-based tests have been developed that are capable of differentiating DENV serotypes and none are currently commercially available. Methodology/Principle findings: We developed an enzyme-linked immunosorbent assay (ELISA) to distinguish DENV-1-4 NS1 using serotype-specific pairs of monoclonal antibodies. A total of 1,046 antibodies were harvested from DENV-immunized mice and screened for antigen binding affinity. ELISA clinical performance was evaluated using 408 polymerase chain reaction-confirmed dengue samples obtained from patients in Brazil, Honduras, and India. The overall sensitivity of the test for pan-DENV was 79.66% (325/408), and the sensitivities for DENV-1-4 serotyping were 79.1% (38/48), 80.41% (78/97), 100% (45/45), and 79.6% (98/123), respectively. Specificity reached 94.07–100%. Significance: Our study demonstrates a robust antibody screening strategy that enabled the development of a serotype NS1-based ELISA with maximized specific and sensitive antigen binding. This sensitive and specific assay also utilized the most expansive cohort to date, and of which about half are from Latin America, a geographic region severely underrepresented in previous similar studies. This ELISA test offers potential enhanced diagnostics during the acute phase of infection to help guide patient care and disease control. These results indicate that this ELISA is a promising aid in early DENV-1-4 diagnosis and surveillance in regions of endemicity in addition to offer convenient monitoring for future vaccine interventions. Author summary: Dengue virus (DENV) infection is an increasingly significant threat to global health, with a yearly estimate of 390 million infections and an expected increasing burden with the rise of climate change and globalization. DENV is caused by one of the four serotypes (DENV-1-4), each of which have been associated with different immune responses and clinical manifestations. We developed a method to detect DENV serotypes by targeting the nonstructural 1 (NS1) antigen through an enzyme-linked immunosorbent-based assay with high sensitivity and specificity. We demonstrate that our high throughput mouse-derived antibody screening method selected for optimal test performance. The antibodies were integrated into an ELISA assay that can distinguish between the four different dengue serotypes by serotype-specific pairing. In addition, we provide a dengue universal antibody combination that enables pan-virus detection independently of the serotype. We use the ELISA in three different countries and calculate overall and site-specific sensitivities and specificities. The assay performs optimally when levels of viremia are high during the first five days of fever. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Multivariate time-series analysis of biomarkers from a dengue cohort offers new approaches for diagnosis and prognosis.
- Author
-
Vasey, Baptiste, Shankar, Anuraj H., Herrera, Bobby Brooke, Becerra, Aniuska, Xhaja, Kris, Echenagucia, Marion, Machado, Sara R., Caicedo, Diana, Miller, John, Amedeo, Paolo, Naumova, Elena N., and Bosch, Irene
- Subjects
DENGUE hemorrhagic fever ,TIME series analysis ,DENGUE ,MULTIVARIATE analysis ,PARTIAL thromboplastin time ,REGRESSION analysis - Abstract
Dengue is a major public health problem worldwide with distinct clinical manifestations: an acute presentation (dengue fever, DF) similar to other febrile illnesses (OFI) and a more severe, life-threatening form (severe dengue, SD). Due to nonspecific clinical presentation during the early phase of dengue infection, differentiating DF from OFI has remained a challenge, and current methods to determine severity of dengue remain poor early predictors. We present a prospective clinical cohort study conducted in Caracas, Venezuela from 2001–2005, designed to determine whether clinical and hematological parameters could distinguish DF from OFI, and identify early prognostic biomarkers of SD. From 204 enrolled suspected dengue patients, there were 111 confirmed dengue cases. Piecewise mixed effects regression and nonparametric statistics were used to analyze longitudinal records. Decreased serum albumin and fibrinogen along with increased D-dimer, thrombin-antithrombin complex, activated partial thromboplastin time and thrombin time were prognostic of SD on the day of defervescence. In the febrile phase, the day-to-day rates of change in serum albumin and fibrinogen concentration, along with platelet counts, were significantly decreased in dengue patients compared to OFI, while the day-to-day rates of change of lymphocytes (%) and thrombin time were increased. In dengue patients, the absolute lymphocytes to neutrophils ratio showed specific temporal increase, enabling classification of dengue patients entering the critical phase with an area under the ROC curve of 0.79. Secondary dengue patients had elongation of Thrombin time compared to primary cases while the D-dimer formation (fibrinolysis marker) remained always lower for secondary compared to primary cases. Based on partial analysis of 31 viral complete genomes, a high frequency of C-to-T transitions located at the third codon position was observed, suggesting deamination events with five major hot spots of amino acid polymorphic sites outside in non-structural proteins. No association of severe outcome was statistically significant for any of the five major polymorphic sites found. This study offers an improved understanding of dengue hemostasis and a novel way of approaching dengue diagnosis and disease prognosis using piecewise mixed effect regression modeling. It also suggests that a better discrimination of the day of disease can improve the diagnostic and prognostic classification power of clinical variables using ROC curve analysis. The piecewise mixed effect regression model corroborated key early clinical determinants of disease, and offers a time-series approach for future vaccine and pathogenesis clinical studies. Author summary: Dengue fever results in a self-limiting, non-specific febrile illness. In approximately 10% of cases, the disease progresses to a severe, life-threatening syndrome. While hematological derangement is a key indicator of dengue, the mechanisms by which pathophysiological changes occur over the course of infection remain unclear. Additionally, there are limited clinical algorithms to facilitate rapid prognosis of dengue. We conducted a prospective clinical cohort study in Caracas, Venezuela to determine whether clinical and hematological parameters could distinguish dengue fever from other febrile illnesses, and identify early prognostic biomarkers of severe disease. Piecewise linear mixed effects regression models demonstrate that rates of change of albumin, fibrinogen, lymphocytes, platelets and thrombin time were significantly different between dengue and other febrile illnesses, and that the absolute value of albumin, fibrinogen, thrombin-antithrombin complex, thrombin time and partial thromboplastin time were prognostic of severe dengue on the day of defervescence. Our study offers extended insights into dengue pathogenesis and provides new approaches to dengue diagnosis and severity prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals.
- Author
-
Herrera, Bobby Brooke, Hamel, Donald J., Oshun, Philip, Akinsola, Rolake, Akanmu, Alani S., Chang, Charlotte A., Eromon, Philomena, Folarin, Onikepe, Adeyemi, Kayode T., Happi, Christian T., Lu, Yichen, Ogunsola, Folasade, and Kanki, Phyllis J.
- Subjects
- *
ANTHRAX toxin , *T cells , *EBOLA virus , *ENZYME-linked immunosorbent assay , *EBOLA virus disease vaccines , *IMMUNE response , *LEUCOCYTES - Abstract
Background: Ebola virus (EBOV) caused more than 11,000 deaths during the 2013–2016 epidemic in West Africa without approved vaccines or immunotherapeutics. Despite its high lethality in some individuals, EBOV infection can produce little to no symptoms in others. A better understanding of the immune responses in individuals who experienced minimally symptomatic and asymptomatic infection could aid the development of more effective vaccines and antivirals against EBOV and related filoviruses. Methodology/Principle findings: Between August and November 2017, blood samples were collected from 19 study participants in Lagos, Nigeria, including 3 Ebola virus disease (EVD) survivors, 10 individuals with documented close contact with symptomatic EVD patients, and 6 control healthcare workers for a cross-sectional serosurvey and T cell analysis. The Lagos samples, as well as archived serum collected from healthy individuals living in surrounding areas of the 1976 Democratic Republic of Congo (DRC) epidemic, were tested for EBOV IgG using commercial enzyme-linked immunosorbent assays (ELISAs) and Western blots. We detected antibodies in 3 out of 3 Lagos survivors and identified 2 seropositive individuals not known to have ever been infected. Of the DRC samples tested, we detected antibodies in 9 out of 71 (12.7%). To characterize the T cell responses in the Lagos samples, we developed an anthrax toxin-based enzyme-linked immunospot (ELISPOT) assay. The seropositive asymptomatic individuals had T cell responses against EBOV nucleoprotein, matrix protein, and glycoprotein 1 that were stronger in magnitude compared to the survivors. Conclusion/Significance: Our data provide further evidence of EBOV exposure in individuals without EVD-like illness and, for the first time, demonstrate that these individuals have T cell responses that are stronger in magnitude compared to severe cases. These findings suggest that T cell immunity may protect against severe EVD, which has important implications for vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Sustained Specific and Cross-Reactive T Cell Responses to Zika and Dengue Virus NS3 in West Africa.
- Author
-
Herrera, Bobby Brooke, Wen-Yang Tsai, Chang, Charlotte A., Hamel, Donald J., Wei-Kung Wang, Yichen Lu, Mboup, Souleymane, and Kanki, Phyllis J.
- Subjects
- *
ZIKA virus infections , *DENGUE viruses , *T cell receptors , *IMMUNE response , *CROSS reactions (Immunology) - Abstract
Recent studies on the role of T cells in Zika virus (ZIKV) infection have shown that T cell responses to Asian ZIKV infection are important for protection, and that previous dengue virus (DENV) exposure amplifies the protective T cell response to Asian ZIKV. Human T cell responses to African ZIKV infection, however, remain unexplored. Here, we utilized the modified anthrax toxin delivery system to develop a flavivirus enzyme-linked immunosorbent spot (ELISPOT) assay. Using human ZIKV and DENV samples from Senegal, West Africa, our results demonstrate specific and cross-reactive T cell responses to nonstructural protein 3 (NS3). Specifically, we found that T cell responses to NS3 protease are ZIKV and DENV specific, but responses to NS3 helicase are cross-reactive. Sequential sample analyses revealed immune responses sustained many years after infection. These results have important implications for African ZIKV/DENV vaccine development, as well as for potential flavivirus diagnostics based on T cell responses. IMPORTANCE The recent Zika virus (ZIKV) epidemic in Latin America and the associated congenital microcephaly and Guillain-Barré syndrome have raised questions as to why we have not recognized these distinct clinical diseases in Africa. The human immunologic response to ZIKV and related flaviviruses in Africa represents a research gap that may shed light on the mechanisms contributing to protection. The goal of our study was to develop an inexpensive assay to detect and characterize the T cell response to African ZIKV and DENV. Our data show long-term specific and crossreactive human immune responses against African ZIKV and DENV, suggesting the usefulness of a diagnostic based on the T cell response. Additionally, we show that prior flavivirus exposure influences the magnitude of the T cell response. The identi- fication of immune responses to African ZIKV and DENV is of relevance to vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Shigella Effector OspB Activates mTORC1 in a Manner That Depends on IQGAP1 and Promotes Cell Proliferation.
- Author
-
Lu, Richard, Herrera, Bobby Brooke, Eshleman, Heather D., Fu, Yang, Bloom, Alexander, Li, Zhigang, Sacks, David B., and Goldberg, Marcia B.
- Subjects
- *
SHIGELLA , *CELL proliferation , *PROTEIN research , *BACTERIAL disease transmission , *PATHOGENIC microorganisms - Abstract
The intracellular bacterial pathogen Shigella infects and spreads through the human intestinal epithelium. Effector proteins delivered by Shigella into cells promote infection by modulating diverse host functions. We demonstrate that the effector protein OspB interacts directly with the scaffolding protein IQGAP1, and that the absence of either OspB or IQGAP1 during infection leads to larger areas of S. flexneri spread through cell monolayers. We show that the effect on the area of bacterial spread is due to OspB triggering increased cell proliferation at the periphery of infected foci, thereby replacing some of the cells that die within infected foci and restricting the area of bacterial spread. We demonstrate that OspB enhancement of cell proliferation results from activation of mTORC1, a master regulator of cell growth, and is blocked by the mTORC1-specific inhibitor rapamycin. OspB activation of mTORC1, and its effects on cell proliferation and bacterial spread, depends on IQGAP1. Our results identify OspB as a regulator of mTORC1 and mTORC1-dependent cell proliferation early during S. flexneri infection and establish a role for IQGAP1 in mTORC1 signaling. They also raise the possibility that IQGAP1 serves as a scaffold for the assembly of an OspB-mTORC1 signaling complex. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Intermediate filaments enable pathogen docking to trigger type 3 effector translocation
- Author
-
Russo, Brian C., Stamm, Luisa M., Raaben, Matthijs, Kim, Caleb M., Kahoud, Emily, Robinson, Lindsey R., Bose, Sayantan, Queiroz, Ana L., Herrera, Bobby Brooke, Baxt, Leigh A., Mor-Vaknin, Nirit, Fu, Yang, Molina, Gabriel, Markovitz, David M., Whelan, Sean P., and Goldberg, Marcia B.
- Abstract
Type 3 secretion systems (T3SSs) of bacterial pathogens translocate bacterial effector proteins that mediate disease into the eukaryotic cytosol. Effectors traverse the plasma membrane through a translocon pore formed by T3SS proteins. In a genome-wide selection, we identified the intermediate filament vimentin as required for infection by the T3SS-dependent pathogen Shigella flexneri. We found that vimentin is required for efficient T3SS translocation of effectors by S. flexneri and other pathogens that use T3SS, Salmonella Typhimurium and Yersinia pseudotuberculosis. Vimentin and the intestinal epithelial intermediate filament keratin 18 interact with the C-terminus of the Shigella translocon pore protein IpaC. Vimentin and its interaction with IpaC are dispensable for pore formation, but are required for stable docking of S. flexneri to cells; moreover, stable docking triggers effector secretion. These findings establish that stable docking of the bacterium specifically requires intermediate filaments, is a process distinct from pore formation, and is a prerequisite for effector secretion.
- Published
- 2016
- Full Text
- View/download PDF
16. Validation of an At-Home Direct Antigen Rapid Test for COVID-19.
- Author
-
Harmon, Alexander, Chang, Celina, Salcedo, Nol, Sena, Brena, Herrera, Bobby Brooke, Bosch, Irene, and Holberger, Laura E.
- Published
- 2021
- Full Text
- View/download PDF
17. Development and Validation of a Rapid Lateral Flow E1/E2-Antigen Test and ELISA in Patients Infected with Emerging Asian Strain of Chikungunya Virus in the Americas.
- Author
-
Reddy, Ankita, Bosch, Irene, Salcedo, Nol, Herrera, Bobby Brooke, de Puig, Helena, Narváez, Carlos F., Caicedo-Borrero, Diana María, Lorenzana, Ivette, Parham, Leda, García, Kimberly, Mercado, Marcela, Turca, Angélica María Rico, Villar-Centeno, Luis A., Gélvez-Ramírez, Margarita, Ríos, Natalia Andrea Gómez, Hiley, Megan, García, Dawlyn, Diamond, Michael S., and Gehrke, Lee
- Subjects
CHIKUNGUNYA virus ,CHIKUNGUNYA ,ENZYME-linked immunosorbent assay ,DIAGNOSIS ,VIRAL antibodies - Abstract
Since its 2013 emergence in the Americas, Chikungunya virus (CHIKV) has posed a serious threat to public health. Early and accurate diagnosis of the disease, though currently lacking in clinics, is integral to enable timely care and epidemiological response. We developed a dual detection system: a CHIKV antigen E1/E2-based enzyme-linked immunosorbent assay (ELISA) and a lateral flow test using high-affinity anti-CHIKV antibodies. The ELISA was validated with 100 PCR-tested acute Chikungunya fever samples from Honduras. The assay had an overall sensitivity and specificity of 51% and 96.67%, respectively, with accuracy reaching 95.45% sensitivity and 92.03% specificity at a cycle threshold (Ct) cutoff of 22. As the Ct value decreased from 35 to 22, the ELISA sensitivity increased. We then developed and validated two lateral flow tests using independent antibody pairs. The sensitivity and specificity reached 100% for both lateral flow tests using 39 samples from Colombia and Honduras at Ct cutoffs of 20 and 27, respectively. For both lateral flow tests, sensitivity decreased as the Ct increased after 27. Because CHIKV E1/E2 are exposed in the virion surfaces in serum during the acute infection phase, these sensitive and specific assays demonstrate opportunities for early detection of this emerging human pathogen. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Systematic Analysis of Bacterial Effector-Postsynaptic Density 95/Disc Large/Zonula Occludens-1 (PDZ) Domain Interactions Demonstrates Shigella OspE Protein Promotes Protein Kinase C Activation via PDLIM Proteins.
- Author
-
Chae-ryun Yi, Allen, John E., Russo, Brian, Soo Young Lee, Heindl, Jason E., Baxt, Leigh A., Herrera, Bobby Brooke, Kahoud, Emily, MacBeath, Gavin, and Goldberg, Marcia B.
- Subjects
- *
ENTEROBACTERIACEAE , *FOOD pathogens , *BIOSYNTHESIS , *BIOMOLECULES , *ORGANIC compounds - Abstract
Diseases caused by many Gram-negative bacterial pathogens depend on the activities of bacterial effector proteins that are delivered into eukaryotic cells via specialized secretion systems. Effector protein function largely depends on specific subcellular targeting and specific interactions with cellular ligands. PDZ domains are common domains that serve to provide specificity in protein-protein interactions in eukaryotic systems. We show that putative PDZ-binding motifs are significantly enriched among effector proteins delivered into mammalian cells by certain bacterial pathogens. We use PDZ domain microarrays to identify candidate interaction partners of the Shigella flexneri effector proteins OspE1 and OspE2, which contain putative PDZ-binding motifs. We demonstrate in vitro and in cells that OspE proteins interact with PDLIM7, a member of the PDLIM family of proteins, which contain a PDZ domain and one or more LIM domains, protein interaction domains that participate in a wide variety of functions, including activation of isoforms of protein kinase C (PKC). We demonstrate that activation of PKC during S. flexneri infection is attenuated in the absence of PDLIM7 or OspE proteins and that the OspE PDZ-binding motif is required for wild-type levels of PKC activation. These results are consistent with a model in which binding of OspE to PDLIM7 during infection regulates the activity of PKC isoforms that bind to the PDLIM7 LIM domain. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.